Greenwich LifeSciences Unveils Promising HLA Data from FLAMINGO-01 Trial

Greenwich LifeSciences has revealed encouraging insights from its Phase III FLAMINGO-01 trial, a study focused on GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences. Early findings show that nearly half of screened patients carry at least one HLA-A*02 allele, a key factor in immune response. With 92% of these patients possessing a second unique HLA type, researchers believe this diversity may provide critical insights into treatment effectiveness. CEO Snehal Patel emphasized that this data allows for a broader evaluation of immune response across different patient groups, which could ultimately refine treatment strategies.

The study’s open-label arm is assessing GLSI-100 in patients without an HLA-A*02 allele, potentially expanding its applicability. Patel noted that deeper analysis of genetic markers might offer a clearer path for personalized immunotherapy approaches. By studying different HLA combinations and their impact on immune response, Greenwich LifeSciences hopes to pinpoint the most responsive patient populations. These findings not only reinforce the trial’s design but also offer valuable direction for the company’s future commercialization strategy.